Business Context and Reporting Period
Company: Alcon, Inc. (NYSE: ACL)
Filing Type: Form 6-K (Report of Foreign Issuer)
Reporting Period: Third Quarter and Nine Months Ended September 30, 2002
Business Overview: Alcon is a global leader in eye care, developing and marketing pharmaceuticals, surgical equipment/devices, and consumer eye care products. The company recently completed its initial public offering (IPO) in March 2002.
Key Financial Metrics
| Metric | Q3 2002 | Q3 2001 | 9M 2002 | 9M 2001 |
|---|---|---|---|---|
| Global Sales | $743.9 million | $676.4 million | $2,259.9 million | $2,077.1 million |
| Net Income | $125.1 million | $71.1 million | $381.9 million | $258.6 million |
| Diluted EPS (Reported) | $0.41 | $0.24 | $1.27 | $0.86 |
| Adjusted Diluted EPS | $0.40 | $0.27 | $1.29 | $0.96 |
| Gross Profit Margin | 71.2% | 71.1% | 70.8% | 71.1% |
| Operating Income | $195.9 million | $137.3 million | $584.4 million | $465.4 million |
| Cash & Equivalents (9/30/02) | $60.6 million | |||
| Total Debt (9/30/02) | $1,079.1 million | |||
| Debt-to-Capital Ratio | 56% (down from 66% prior quarter) |
Material Changes vs. Prior Period
- Revenue Growth: Q3 sales increased 10.0% year-over-year (9.3% excluding foreign exchange). Nine-month sales rose 8.8% (9.6% excluding FX).
- Profitability: Reported net income surged 76% in Q3 and 48% for the nine-month period. Adjusted EPS grew 48.1% in Q3 and 34.4% year-to-date.
- Product Line Performance:
- Pharmaceuticals: Q3 sales up 21.6%. Glaucoma products (led by Travatan) rose 27.1%. Allergy products (Patanol) grew 37.9% due to severe allergy seasons.
- Surgical: Q3 sales up 5.8%. Intraocular lenses (IOLs) grew 10.4%. Refractive revenues declined 27.6% due to weak consumer confidence and global economic conditions.
- Consumer Eye Care: Q3 sales declined 1.1% due to weakness in the soft contact lens disinfectant market.
- Expense Management: SG&A expenses decreased 1.6% in Q3, improving to 32.1% of sales from 35.8% in the prior year. R&D expenses increased 8.3% due to new project funding.
- Accounting Changes: Adoption of FASB Statement #142 eliminated goodwill amortization, positively impacting earnings compared to 2001.
Guidance, Outlook, and Risks
- 2002 Full Year Guidance: Sales on track to hit $3 billion. Adjusted diluted EPS guidance raised to $1.54 - $1.57.
- 2003 Outlook: Projected sales of $3.25 - $3.27 billion. Projected diluted EPS of $1.79 - $1.82.
- Management Commentary: CEO Tim Sear highlighted the pharmaceutical business as the growth leader, noting that product breadth offsets weakness in other areas. The refractive market remains soft but received a boost from FDA approval of CustomCornea technology.
- Key Risks & Contingencies:
- Refractive Market: Adversely impacted by global economic conditions and weak consumer confidence.
- Regulatory/Litigation: Pending litigation and product recalls could impact results. (Note: Travatan patent litigation with Pharmacia was settled in October).
- Currency: Foreign exchange fluctuations may negatively affect financial results.
- Equity Restructuring: Alcon plans to sell Series A and B preferred shares of its U.S. subsidiary (AHI) to financial investors to improve liquidity and flexibility.
Investor Verification Checklist
- Refractive Segment Recovery: Verify if the FDA approval of CustomCornea technology translates to revenue growth in the soft refractive market.
- Pharmaceutical Growth Sustainability: Confirm if the double-digit growth in glaucoma (Travatan) and allergy (Patanol) products is sustainable beyond seasonal factors.
- Debt Reduction Strategy: Monitor the execution of the AHI preferred share sale and its impact on the debt-to-capital ratio.
- One-Time Adjustments: Review the reconciliation of reported vs. adjusted EPS to understand the impact of the IPO-related charges and FASB 142 adoption.
- Share Repurchase Program: Track the utilization of the newly authorized $2 million share repurchase program for treasury stock.